StimCardio Medical
StimCardio Medical is developing a non-invasive, wearable neuromodulation platform designed for continuous at-home use, with atrial fibrillation as its lead indication. The system integrates continuous optical and EKG sensing with cloud-based analysis to deliver personalized, closed-loop peripheral neuromodulation aimed at reducing AF burden. In the NEUROPULSE pilot study, the approach demonstrated 90.0% freedom from atrial arrhythmias at six months post-ablation, compared to 80.8% with sham.
- Medical Devices
- Healthcare Technology
- Digital Health
- Internet of Things
- Hardware
- Software Only
Funding
Raised to date
$30MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
$30M · Series A
Announced Oct 2026 · from article date
Disclosed cumulative: $30M
Founders
Founder details are not available yet.
Product
Problem
Atrial fibrillation is a highly prevalent cardiac arrhythmia affecting over 52.5 million people worldwide, with patients facing a roughly five-fold increased risk of stroke and a one-in-three-to-five lifetime risk of developing the condition. Current treatment approaches, including catheter ablation, often face recurrence rates that leave patients vulnerable to ongoing arrhythmia burden, and existing neuromodulation therapies are invasive or require clinical settings, limiting their use in everyday life.
Solution
StimCardio Medical is developing a non-invasive, wearable neuromodulation platform designed for continuous use in daily life, beginning with atrial fibrillation as its lead indication. The integrated system continuously monitors cardiac and autonomic signals through optical and electrical (EKG) sensors, analyzes physiological data in the cloud, and delivers personalized peripheral neuromodulation to restore autonomic balance and reduce AF burden. By modulating peripheral pathways that influence the autonomic nervous system, the platform improves heart-brain communication and enables adaptive therapy informed by individual rhythm patterns. Clinical evidence from the NEUROPULSE pilot study demonstrated 90.0% freedom from atrial arrhythmias at six months following ablation with median nerve stimulation, compared to 80.8% with sham, supporting the platform's potential to meaningfully reduce AF recurrence.
Target Audience
Primary customers are electrophysiologists, cardiologists, and cardiac care providers treating patients with atrial fibrillation, particularly those who have undergone catheter ablation and face risk of arrhythmia recurrence. The platform is also designed for patients seeking a non-invasive, continuous therapy option for long-term AF management.
Features
- Wearable, non-invasive form factor designed for continuous at-home and everyday use
- Integrated optical and electrical (EKG) sensors for real-time cardiac and autonomic signal monitoring
- Cloud-based physiological data analysis enabling continuous arrhythmia detection and adaptive therapy
- Personalized peripheral neuromodulation targeting median nerve pathways to influence autonomic nervous system activity
- Closed-loop system that adjusts stimulation based on individual rhythm patterns and real-time physiological feedback
- Clinical validation through multiple completed studies, including a randomized, double-blinded, sham-controlled pilot (n=77) and a first-in-human home-use feasibility study